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Proteasome inhibitors (PIs) are now standard of care for several cancers, and noninvasive biomarkers of 
treatment response are critically required for early patient stratification and treatment personalization. 
The present study evaluated whether chemical exchange (CEST) magnetic resonance imaging (MRI) 
can provide measurements that can be used as the noninvasive biomarkers of proteasome inhibition, 
alongside diffusion MRI and relaxometry. The sensitivity of human colorectal carcinoma cells to the 
PI Ixazomib was assessed via in vitro and in vivo dose-response experiments. Acute in vivo response 
to Ixazomib was assessed at three dosing concentrations, using CEST MRI (amide, amine, hydroxyl 
signals), diffusion MRI (ADC) and relaxometry (T1, T2). These responses were further evaluated with the 
known histological markers for Ixazomib and Bradford assay ex vivo. The CEST signal from amides and 
amines increased in proportion to Ixazomib dose in colorectal cancer xenografts. The cell lines differed 
in their sensitivity to Ixazomib, which was reflected in the MRI measurements. A mild stimulation 
in tumor growth was observed at low Ixazomib doses. Our results identify CEST MRI as a promising 
method for safely and noninvasively monitoring disrupted tumor protein homeostasis induced by 
proteasome inhibitor treatment, and for stratifying sensitivity between tumor types.
Loss of protein homeostasis is associated with a range of pathological conditions including most forms of demen-
tia1, amyloidosis2 and cancers3. In cancer, malignant cells exhibit an abnormally high turnover of protein, which 
is most notably exploited as a therapeutic target by proteasome inhibitors (PIs)4. By inhibiting the action of pro-
teasomes, PIs disrupt protein homeostasis, resulting in apoptotic cell death5. PIs are now in routine clinical use 
for treating hematological malignancies6–8, and there is increasing interest in the use of proteasome inhibition as 
a therapeutic target in solid tumors9–14.
The translation of novel therapies into the clinic requires noninvasive biomarkers of successful response to 
therapy, to enable safe, longitudinal monitoring of disease progression. Assessing response to Pl therapy is cur-
rently evaluated invasively (via immunohistochemistry of biopsied tumor tissue)15, or radiologically with longitu-
dinal measurements of tumor size16. However, such changes in tumor volume can take weeks or months to occur, 
and so biomarkers that provide a much earlier measurement of response would be extremely valuable. Here, we 
propose a new set of noninvasive imaging biomarkers for detecting disrupted protein homeostasis, resulting from 
PI therapy, which are based on magnetic resonance imaging (MRI). In particular, we have focused on chemical 
1Centre for Advanced Biomedical Imaging, Division of Medicine, University College London, London, WC1E 6DD, 
United Kingdom. 2Neuroscience, Physiology & Pharmacology, University College London, London, WC1E 6BT, 
United Kingdom. 3Cancer Institute, University College London, London, WC1E 6DD, United Kingdom. 4Cancer 
Pharmacology, Takeda Pharmaceutical International Corporation, Cambridge, MA, 02139, United States. 5Institute 
of Neurology, University College London, London, WC1N 3BG, United Kingdom. 6Biomedical Imaging Group, Takeda 
Pharmaceutical International Corporation, Cambridge, MA, 02139, United States. Correspondence and requests for 
materials should be addressed to S.W.-S. (email: simon.walkersamuel@ucl.ac.uk)
Received: 13 February 2018
Accepted: 2 October 2018
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2SCIentIfIC REPoRTS |  (2018) 8:15068  | DOI:10.1038/s41598-018-33549-x
exchange saturation transfer (CEST) MRI, which has previously been used to detect changes in protein content 
in cancer17–19. CEST image contrast can be tuned to reflect the exchange of protons between water and various 
chemical groups, including amides (in protein backbones), amines, guanidinium and hydroxyls20. This enables 
the small signal from solutes containing such groups to be amplified via the much larger water pool signal. We 
hypothesized that successful proteasome inhibition, and associated protein accumulation4,21, would result in an 
increase in CEST signal of amide and amine chemical groups.
Alongside CEST, we evaluated a range of quantitative, noninvasive MRI measurements (diffusion MRI, T1 
and T2 relaxometry), in LS174T and SW1222 xenograft models of human colorectal carcinoma. In vivo measure-
ments of acute (up to 72 hours) dosing with Ixazomib, at three different dose concentrations, were undertaken 
and compared with gold-standard histological measures5,22,23. Biological validation studies, such as undertaken 
here, are a vital component of the roadmap for the translation of imaging biomarkers into the clinic24. Our study 
focuses on Ixazomib (Ninlaro®/MLN2238/MLN9708, Takeda Pharmaceuticals Company Limited), which is the 
first orally-available PI therapy10,25 with approval for use in the United States, Europe and Japan for combinational 
treatment in multiple myeloma25,26. Ixazomib has also shown promise in solid tumor rodent models, including 
colorectal tumors9–14.
The aims of our study were to: (1) determine the efficacy of Ixazomib in colorectal carcinoma cell lines and 
murine xenografts; and (2) evaluate the ability of noninvasive MRI measurements to evaluate this response in 
vivo, with a view to their translation into the clinic.
Results
LS174T and SW1222 human colorectal cancer cell lines displayed differing in vitro sensitivities 
to Ixazomib. The MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) assay showed that 
both SW1222 and LS174T cell lines demonstrated a significant decrease in viability at doses greater than 12 nM 
in SW1222 and 24 nM in LS174T cells (Fig. 1), at 24, 48 and 72 hours. Interestingly, both cell lines also exhibited 
a stimulatory response at low doses (<6 nM in SW1222 and <24 nM in LS174T), evidenced by an increase in cell 
viability (130% in SW1222 and 120% in LS174T) that peaked at 48 hours. Overall, SW1222 cells were more sensi-
tive to Ixazomib than LS174T cells (IC50 of 12.6 nM and 41.1 nM for SW1222 and LS174T, respectively), with an 
approximately three-fold lower viability at 48 hours, and approximately ten-fold lower viability at 72 hours (IC50 
of 7.6 nM and 78.4 nM for SW1222 and LS174T, respectively).
Ixazomib affected colorectal tumor xenograft growth in vivo, in a dose-dependent man-
ner. We next investigated the action of Ixazomib in vivo, at 24 and 72 hours after dosing with Ixazomib (at 11, 
9.5 or 8 mg kg−1) or vehicle. MRI measurements of tumor volume confirmed that the growth of both SW1222 
and LS174T tumors was significantly inhibited following Ixazomib doses of 9.5 and 11 mg kg−1 relative to control 
tumors (Figs 2 and S1). We also observed a small but significant increase in tumor volume at 72 hours (relative to 
baseline) at the lowest Ixazomib dose (8 mg kg−1) in both SW1222 (P < 0.0001) and LS174T (P < 0.001) tumors, 
which potentially mirrors the low-dose stimulatory effect that were observed in in vitro experiments.
CEST MRI measurements reflected response to proteasome inhibition in colorectal cancer xen-
ografts. CEST MRI measurements were represented using Z-spectra, a plot of normalized water signal as a 
function of saturation frequency offset (Fig. 3a). Our assignment of exchange peaks in Z-spectra is described in 
the Methods section, and consisted of amide, amine (possibly also containing a contribution from guanidinium) 
and hydroxyl groups, located at approximately 3.5, 2.4 and 1.2 ppm from water, respectively27–29. We also assigned 
a single, broad peak corresponding to contributions from magnetization transfer (MT, −2.4 ppm27), relayed 
nuclear Overhauser effect (NOE, −3.3 ppm30) and lipids (−1 to −5 ppm29), which we refer to as NOE/MT. Fitting 
our summed Lorentzian model on a pixel-by-pixel basis allowed images of each Z-spectrum contribution to be 
generated (Fig. 3b). The stability of baseline frequency during Z-spectrum acquisition was found to be within 0.1 
ppm (see Supplementary Information), and representative T2-weighted and CEST reference images are shown 
in Fig. 3c.
The area under amide and amine peaks significantly increased following Ixazomib treatment, relative to 
pre-treatment measurements (Figs 4 and S1). A summary of all significant changes, for each tumor type, Ixazomib 
dose and time post-dosing is provided in Fig. 5. These data, in combination, demonstrate the smaller magnitude 
of change in parameter values following treatment in LS174T tumors compared with SW1222 tumors, potentially 
reflecting their lower sensitivity to Ixazomib.
Changes in amide and amine peaks were significantly correlated with Ixazomib dose. A signif-
icant correlation was found between amide peak area and Ixazomib dose in SW1222 tumors at 72 hours (r = 0.98, 
P < 0.05) (Fig. 4). This was also reflected in the change in the amine area of the Z-spectrum, with a strong positive 
correlation between the dose concentration and amine signals (r = 0.97, P < 0.05). Conversely, no parameters in 
LS174T tumors exhibited a dose-dependent response, which could reflect their reduced sensitivity to Ixazomib, 
compared with SW1222 tumors.
Gross tissue protein measurements from Bradford assay displayed a complex relationship with 
Ixazomib dose. Bradford assay at 72 hours showed a significant difference in mean protein concentration 
between SW1222 and LS174T control tumors (1386 μg ml−1, P < 0.001). Both SW1222 and LS174T tumors had a 
small but significantly lower protein concentration than control tumors when dosed at 8 mg kg−1, whereas higher 
doses did not induce a significant change (Fig. 6c).
No significant correlation was found between Bradford assay results and in vivo amide and amine peak area 
(P > 0.05, Spearman’s rho). Equally, no significant differences were found in baseline CEST parameters, between 
tumors, which could have reflected the difference found between tumor types in Bradford assay results.
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Diffusion MRI measures reflected changes in CEST parameters, but T1 and T2 showed mixed 
changes. A significant increase was found in ADC from baseline, in SW1222 tumors at 72 hours, for Ixazomib 
doses of 9.5 and 11 mg kg−1 (41.5%, P < 0.01 and 22.1%, P < 0.05, respectively), which were significantly greater 
than control tumors (Figs 4 and 5). The change in ADC from baseline was also significantly correlated with 
Ixazomib dose (P < 0.01). In LS174T tumors, only the 9.5 mg kg−1 group showed a significant increase, when 
compared against baseline (55.19%, P < 0.001) and control tumors (46.92%, P < 0.05).
T1 and T2 showed a more mixed set of changes in both tumor types, with fewer time points achieving signif-
icance (see Figs 4 and 5). T1 and T2 showed both increases and decreases over time, and did not display a simple 
relationship with Ixazomib dose, other than for the change in T2 in SW1222 tumors at 72 hours, which was 
directly correlated with dose (r = 0.99, P < 0.01).
Immunohistochemical markers of apoptosis significantly correlated with Ixazomib dose in 
SW1222, but not LS174T tumors. To evaluate the relationship between CEST imaging biomarkers 
and physiological changes caused by proteasome inhibition, we used immunohistochemistry to measure the 
percentage expression of cell death factor, caspase 3, and GADD34. Our results revealed significantly higher 
Figure 1. Dose-response curves showing cell viability as a function of Ixazomib concentration, measured 
with the MTT assay, at 24, 48 and 72 hours post-dosing, in SW1222 (n = 12) (a) and LS174T (n = 12) (b) 
cells (data points are mean ± standard error). These in vitro results show that cell viability decreases at higher 
Ixazomib doses (>12 nM in SW1222 and >24 nM in LS174T) and that growth is stimulated at lower doses 
(<6 nM in SW1222 and <24 nM in LS174T). SW1222 cells are more sensitive to Ixazomib than LS174T cells, 
which is in keeping with their K-Ras mutation status. Dashed lines show the Ixazomib binding estimates, 
which is a measure of the percentage of receptors that remain unbound (using (Ki = 0.93 nM, as a function of 
concentration; as concentration increases, the greater the percentage saturation of binding sites5). Data points 
are mean ± standard error.
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caspase 3 expression in SW1222 tumors for doses of 9.5 mg kg−1 (25.61%, P < 0.05) and 11 mg kg−1 (29.87%, 
P < 0.01), relative to controls (Fig. 6). Caspase 3 expression was also significantly correlated with Ixazomib dose 
(r = 0.95, P < 0.05). Though small, there was significantly lower caspase 3 expression in LS174T tumors for a dose 
of 8 mg kg−1 (4.57%, P < 0.05), relative to controls, but no significant differences at higher doses. Whilst there was 
no significant change in GADD34 percentage expression relative to controls in either SW1222 or LS174T tumors 
(Fig. 6), as for caspase 3, a significant correlation was found between GADD34 expression with increasing dosing 
concentration in SW1222 tumors (r = 0.96, P < 0.05).
Discussion
Noninvasive imaging biomarkers for cancer therapy are critically needed in the clinic, particularly those that can 
detect a functional response prior to much slower changes in tumor volume24. CEST is a noninvasive imaging 
technique, based on MRI, in which image contrast is induced via the exchange of protons between water and 
chemical groups such as amides, amines and hydroxyls20. The presence of amide groups in protein backbones and 
amine groups on peptides make CEST sensitive to changes in the concentration of both types of molecules5,31–34, 
and thus as a potential biomarker of disrupted protein homeostasis. We therefore aimed to evaluate the change in 
CEST MRI parameters (alongside other more conventional MRI measures) following dosing with Ixazomib, in 
two colorectal carcinoma tumor xenograft models (SW1222 and LS174T).
Our experiments showed that Ixazomib elicited a significant growth-inhibitory effect in both colorectal cell 
lines, as evidenced by a reduction in cell viability in vitro and the reduction of tumor growth rates in vivo. SW1222 
tumors were found to be more sensitive to Ixazomib than LS174T tumors, which could be due to their different 
K-Ras mutations: SW1222 cells have a K-Ras mutation at A146V35, compared with G12D for LS174T tumors36, 
which has been proposed to infer a greater sensitivity to proteasome inhibition9. In addition, the microenviron-
ment of the two tumor types could provide a source of resistance in vivo, with LS174T tumors being less vascular, 
less differentiated and less perfused than SW1222 tumors37–39.
Our CEST measurements showed a significant increase in amide, amine and hydroxyl peak areas with time 
following Ixazomib treatment, with the greatest effects observed at 72 hours following dosing. Moreover, sev-
eral parameters varied in a dose-dependent manner, with a significant correlation measured between amide and 
amine peak size and Ixazomib dose in SW1222 tumors. This reflected similar trends in our immunohistochemical 
measurements of caspase 3 and GADD34 expression, which were themselves consistent with previous studies5,23. 
This induction of apoptosis could also explain the observed increases in ADC, in which changes in cell size and 
the induction of micro-necrosis causes less restricted water diffusion37. However, the relationship between CEST 
parameters and Bradford assay were less straightforward to interpret, with no apparent correspondence evident 
between the two measurement types. Several factors might help to explain this disparity. Firstly, CEST MRI is 
sensitive to mobile protein and peptides, whereas the Bradford assay is unaffected by amino acids or peptides 
smaller than 3 kDa (according to manufacturer’s instructions). Secondly, CEST contrast is dependent on several 
other parameters including T1, T2 and pH, which were not controlled for in this study. T1 and T2 were found to 
show few consistent changes when measured directly, so it is arguable that these were unlikely to have influenced 
CEST measurements significantly. The pH of tumor tissue could also have influenced our measurements, and 
a fully quantitative model27 could potentially be implemented to separate proton exchange rate and pool sizes. 
Interestingly, we found evidence that Ixazomib causes a mild stimulatory effect at low doses40. This bi-phasic 
effect has been previously observed in a wide range of anticancer agents40–42 alongside physical interventions 
such as radiotherapy43. In vitro MTT assays revealed increased cell viability at low doses, and tumor growth was 
Figure 2. Mean relative change in tumor volume as a function of Ixazomib dose, at 72 hours post-dosing, in 
LS174T and SW1222 human colorectal carcinoma mouse xenografts. Tumor growth was significantly inhibited 
at the two highest doses investigated (9.5 and 11 mg kg−1), and mildly (but significantly) stimulated at the 
lowest dose (8 mg kg−1). Tumor volumes were measured using volumetric MRI, and error bars represent the 
standard error in each measurement; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 (two-way ANOVA); 
*compared to baseline (pre-dosing) measurement, ^compared to measurement at 24 hours after Ixazomib dose, 
+compared to control measurement.
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Figure 3. Example MRI measurements in SW1222 and LS174T tumors, prior to and at 24 and 72 hours 
following treatment with Ixazomib, showing increasing amide and amine peak areas, alongside increasing 
apparent diffusion coefficient (ADC). (a) Z-spectra from CEST MRI, showing the normalised MRI signal 
intensity as a function of saturation frequency offset, averaged over a single representative tumor dataset 
at baseline and 24 and 72 hours following dosing with 11 mg kg−1 of Ixazomib. Data points were fitted to a 
Bayesian model that allowed the individual influence of proton exchange between water and amide, amine 
and hydroxyl groups to be isolated (1.2, 2.4 and 3.5 ppm, respectively), alongside the combined effect of 
magnetisation transfer (MT, −2.4 ppm) and nuclear Overhauser effect (NOE, −3.3 ppm). Water peaks (0 
ppm) have been removed for clarity. (b) Images of amide, amine hydroxyl, MT and water peak areas, acquired 
noninvasively in an example SW1222 tumor at baseline and post-therapy (24 and 72 hours). Maps of the 
apparent diffusion coefficient (ADC) from diffusion MRI measurements and the transverse relaxation time (T2) 
are also shown. (c) Representative T2-weighted (left) and CEST reference images (right).
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slightly enhanced at an in vivo dose of 8 mg kg−1. Likewise, caspase 3 expression was slightly decreased, relative to 
controls, in LS174T tumors dosed at 8 mg kg−1. Whether this effect was reflected in MRI measurements is unclear, 
as no significant changes were observed in CEST parameters (amide and amine areas) at low Ixazomib doses. 
However, this effect warrants further investigation, particularly if the treatment of tumors with poor delivery 
profiles (for example, pancreatic adenocarcinoma) is currently under consideration, as delivered doses might be 
significantly lower than expected. In this context, in particular, amide and amine CEST signals and ADC could 
find strong utility, alongside complementary measures of blood flow and interstitial transport.
A limited number of studies have previously identified CEST MRI as a potential biomarker of response to 
anti-cancer therapies. Sagiyama et al. demonstrated that amide signal proportionally decreased with Ki67 (a 
marker of cell proliferation) in brain tumor models following temozolomide (TMZ) treatment44, and the authors 
suggested that CEST MRI be used for the non-invasive detection of therapeutic response. Another study sug-
gested the biomarker potential of CEST MRI in high intensity focused ultrasound (HIFU) treatment, after 
observing reduced amide signals in HIFU-treated animal models45. Both of these studies demonstrated a decrease 
in amide signal following therapy, which contrasts with our observation of an increase. The cause of this is pos-
sibly due to the different analysis approach used in the current study; in conventional CEST MRI asymmetry 
analysis, the portion of the Z-spectrum with a frequency greater than water is subtracted from the portion with a 
frequency lower than water, to produce a magnetization transfer asymmetry (MTRasym) spectrum, which forms 
the basis of further spectral analysis20.
In the current study, individual exchange peaks were individually fitted, allowing the influence of amide, 
amine and hydroxyl groups, alongside NOE and MT effects, to be isolated. However, it is possible that other 
chemical groups could also have contributed to these peaks; for example, guanidinium groups have been 
proposed to contribute an exchange peak at ~2 ppm, which could overlap with our assigned amide peak46,47. 
Figure 4. Summary of changes in quantitative, non-invasive MRI parameters, as a function of Ixazomib 
dose (8, 9.5 and 11 mg kg−1), at 72 hours post-dosing. Only CEST measurements associated with amines and 
amide groups show a correspondence with Ixazomib dose. Significant increases, in a dose-dependent manner, 
were observed in amine and amide peak areas from CEST MRI measurements. Tumor apparent diffusion 
coefficient (ADC) also increased significantly for the two highest doses, and T2 decreased significantly in 
LS174T tumors only (the top and bottom set of asterisks or crosses represents LS174T and LS174T, respectively, 
where two mean values overlap). Data points are mean ± standard error; *P < 0.05, **P < 0.01, ***P < 0.001, 
****P < 0.0001 (two-way ANOVA); *compared to baseline, ^compared to measurement at 24 hours post-
Ixazomib dose, +compared to control.
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Likewise, we chose to combine MT and NOE effects into a single, broad peak, as this was found to provide greater 
model stability than fitting both influences independently.
A novel Bayesian summed Lorentzian model enabled semi-quantitative analysis of the CEST data in this 
study. This model is useful as it provides a straightforward and precise characterization of the signal, but also 
suffers from some limitations. For example, it is phenomenological in nature, and parameter estimates are specific 
to the B1 power used (3 μT RMS, here). Moreover, the coalescence of exchange and water peaks cannot be easily 
resolved, which could have affected the quantification of hydroxyl peaks, in particular, and so these data should 
be treated with more caution than those associated with peaks further removed from water (such as amides). To 
account for these effects would require a more complex, parametric exchange model (for example, the Bayesian 
model proposed by Chappell et al.27. This approach would also enable a more rigorous evaluation of T1 changes 
that were concomitant with changes in other parameters, beyond the bulk T1 measurements undertaken here.
In the current study, individual exchange peaks were individually fitted, allowing the influence of amide, 
amine and hydroxyl groups to be isolated. A limitation to our model was the combining of NOE and MT effects 
into a single Lorentzian peak, which was determined to provide greater model stability than two separate 
Lorentzians during our initial model development. However, MT could most likely be modeled as a constant 
offset in future analyses, due to its broad line shape, thereby allowing MT effects to be modeled independently.
A key question is whether these findings can be translated and reproduced in humans. Clinical MRI is typi-
cally undertaken at field strength of 3T, which is lower than the 9.4T system used here. Translation between field 
strengths presents several challenges (such as reduced separation between exchange peaks, lower signal-to-noise 
Figure 5. Summary of significant changes (P < 0.05) in each quantitative parameter measured, relative to 
controls. Dark blue or red cells indicate a significant increase, light blue or red cells indicate a significant 
decrease, white cells no significant change, and grey cells show where no data were available. *P < 0.05, 
**P < 0.01, ***P < 0.001, ****P < 0.0001 (two-way ANOVA); *compared to baseline, ^compared to 
measurement at 24 hours post-Ixazomib dose, +compared to control.
www.nature.com/scientificreports/
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ratios, and slower relaxation rates), but which have been overcome in other translational studies24,48. Equally, the 
evaluation of Ixazomib in human solid tumors is at an early stage and the data presented here demonstrates its 
efficacy in two colorectal carcinoma xenograft models. It also identifies several promising, noninvasive biomark-
ers (amide and amine CEST signals and ADC) that could be explored for determining early treatment response 
and detecting disrupted protein homeostasis. In addition, they could be further evaluated in the assessment of 
plasma cell malignancies (currently the predominant targets of Ixazomib), with a view to reducing the need for 
invasive bone marrow aspirates or biopsy.
Materials and Methods
Cell culture. SW1222 and LS174T cells were cultured in minimum essential medium eagle (MEME, M4655, 
Sigma-Aldrich Cell Culture, UK) with 5% fetal bovine serum. On the day of inoculation, the cells were harvested 
by washing once in phosphate buffered saline (PBS) solution (Sigma-Aldrich Cell Culture, UK) and trypsinised 
at 37 °C for 5 minutes. The cells were pelleted by suspending in MEME and centrifuged at 1600 × g for 5 min-
utes. The suspension mixture was removed and the pelleted cells were washed in PBS and then in serum-free 
media at 1600 × g for 5 minutes. Before the final wash in serum-free medium, 10 µL of the cell suspension mixed 
with trypan blue (Invitrogen, Thermo Fisher Scientific, USA) was transferred to a cell counting chamber slide 
(Invitrogen, Thermo Fisher Scientific, USA) and cells were counted with a Countess Automated Cell Counter 
(Invitrogen, Thermo Fisher Scientific, USA). The cells pelleted after the final wash were suspended in known 
volume serum free-media.
In vitro MTT assay. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (Vybrant® MTT 
Cell Proliferation Assay Kit, Life Technologies, Thermo Fisher Scientific, USA) reagent at 12 mM was prepared 
according to manufacturer’s instructions. Before treatment, 10,000 cells were seeded in 100 µL of complete media 
per well, for 9 hours, in a clear polystyrene 96-well flat bottom microplate (Greiner Bio-One, Austria).
Figure 6. Ex vivo analysis of resected tumor tissue. Images of (a) caspase 3 and (b) GADD34 expression at 
72 hours following dosing with vehicle, 8 mg kg−1, 9.5 mg kg−1 or 11 mg kg−1. Caspase 3-positive nuclei are 
stained brown (as labeled with a red arrow) and blue otherwise (haematoxylin), and example necrotic areas 
are labeled with a yellow arrow. GADD34-positive areas are stained brown and nuclei are counter-stained in 
blue with haematoxylin. (c) The results of Bradford assay, to measure gross tissue protein. Summary data from 
quantitative analysis of immunohistochemistry images are shown for caspase 3 (d) and GADD34 (e), for each 
study group. The scale bar in (a and b) represents 100 μm. Data points are mean ± standard error (*P < 0.05, 
**P < 0.01, ordinary one-way ANOVA of Mann-Whitney test).
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Ixazomib was diluted in complete media from 400 to 1.6 nM using 2-fold serial dilution. Media in each well 
was removed and replaced with 90 µL of Ixazomib, with corresponding concentration. Cells were left for 24, 48 or 
72 hours, then labeled with 10 µL of the MTT reagent, and their absorbance were measured, according to instruc-
tions (see supplemental methods).
Cell viability was estimated from the absorbance measure (unitless) as a percentage of the mean absorbance of 
control cells. These data were fitted to the modified Hill equation, from which the EC50 (half-maximal stimulatory 
concentration) and IC50 (half-maximal inhibitory concentration) were estimated (see supplemental methods for 
details).
Animal models. All in vivo experiments were performed in accordance with the UK Home Office Animals 
Scientific Procedures Act, 1986 and United Kingdom Coordinating Committee on Cancer Research (UKCCCR) 
guidelines49. All experimental protocols were approved by the University College London Animal Ethics 
Committee. Mice had access to food and water ad libitum. 5 × 106 SW1222 or LS174T cells were subcutaneously 
inoculated (0.1 mL per injection) on the lower right flank of 6–8 weeks old female CD1 nu/nu mice (Charles River 
Laboratories, UK).
In vivo experimental design. Tumors were allowed to grow for 14–16 days, then randomly assigned to 
treatment and control groups. The treatment group received a single dose of Ixazomib i.v., at 8, 9.5 or 11 mg kg−1 
(n = 6, 5, 14, respectively). The control group (n = 5, 5, 7 for the treated 8, 9.5 and 11 mg kg−1, respectively; total 
n = 17) received vehicle, consisting of the drug stock solution (2-Hydroxypropyl-β-cyclodextrin, Sigma Aldrich, 
USA). Treated mice were maintained in a warmed cage using a thermostatic heating pad (Physitemp Instruments, 
Inc., USA) and an infrared heating lamp (Zoo Med, UK) providing an ambient temperature of 24–26 °C. Hydrogel 
was provided to prevent dehydration. Tumor volume (V) was measured every 2 days using electronic calipers, 
according to50 V = w2l/2, where l and w are the maximal tumor diameter and the diameter orthogonal to this 
measurement, respectively. The mass of each mouse was also measured using an electric balance (C-MAG HS 7 
IKAMAG®, Germany).
Baseline MRI data were acquired 24 hours before drug administration (0 hours), with follow-up sessions at 48 
and 72 hours. Immediately following the final MRI scan, mice were culled via cervical dislocation, tumors were 
resected and sent for ex vivo analysis.
In vivo MRI protocol. MRI data were acquired using a 9.4 T scanner (Agilent, USA) with a 39 mm birdcage 
coil (Rapid MR International, USA). Mice were anaesthetized prior to and throughout each scanning session 
using isoflurane in O2 (2.5% for induction, 1.25–1.75% for maintenance). Core body temperature was main-
tained 37 °C using a warm water heating system. Ventilation rate was monitored using a respiration pad (SA 
Instruments, USA) and maintained at 60–80 breaths per minute by adjustment of isoflurane concentration.
Following shimming, a T2-weighted, fast spin echo sequence was used for tumor localization and volume 
measurement (see supplemental methods for details).
CEST MRI. Our CEST sequence was based on a gradient echo acquisition with the following parameters: repe-
tition time (TR), 162 ms; echo time (TE), 2 ms; RMS saturation power, B1,rms, 3 µT; flip angle, 20°; slice thickness, 
1 mm (single slice); matrix size, 64 × 64; FOV, 30 × 30 mm2, acquisition time, 8 minutes. The slice was positioned 
to encompass the largest cross-sectional area of each tumor. Sampling of each line of k-space was preceded by 
a train of three 50 ms Gaussian pulses to induce saturation, with no dummy scans. We have previously shown 
that 100 saturation pulses, applied within the outer third of k-space, enable a steady state to be reached28. Each 
pulse had a flip angle of 20°, duration of 2 ms and with 2 ms spacing28. Crusher gradients were applied between 
pulses to spoil any residual transverse magnetization. The sequence was repeated with saturation frequency 
offsets ranging from −6 to 6 ppm, at intervals of 0.12 ppm. A reference image was also acquired at an offset of 
8000 ppm (S0).
During post-processing, Z-spectra were produced on a pixel-by-pixel basis, according to Z(f) = S(f)/S0, where 
f is the saturation offset frequency. These data were fitted with a summed Lorentzian model51, with peak offsets 
corresponding to proton exchange between water and amide, amine (plus a potential contribution from guan-
idinium groups) and hydroxyl groups, alongside a broad peak corresponding to magnetization transfer, nuclear 
Overhauser effect (NOE) and lipids. Details of this modeling step are provided in the supplemental methods.
Diffusion MRI and relaxometry. Full details of diffusion MRI, T1 and T2 acquisition and quantification proce-
dures are provided in the supplemental materials. In brief, diffusion MRI data were acquired using a multi-slice 
fast spin-echo sequence, with b-values ranging from 150 to 1070 s mm−2 and acquisition time of 6 minutes. The 
apparent diffusion coefficient was quantified from these data by fitting to a simple exponential function (equ. 5). 
T1 and T2 were estimated from data acquired with a Look-Locker52 segmented inversion recovery sequence and a 
multi-echo multi-slice spin-echo sequence (acquisition time of 7 and 4 minutes, respectively).
Ex vivo analysis of resected tumor samples. Resected tumors were cut in half: one half was flash-frozen 
in liquid nitrogen and stored at −80 °C (for Bradford Assay) and the other half was fixed in 5% formalin for 
immunohistochemical analysis.
Bradford Assay. Tumor protein was extracted (T-PER® Tissue Protein Extraction Reagent, Thermo Fisher 
Scientific, USA) and Bradford assays were carried out (Pierce Coomassie Bradford Protein Assay Kit, Thermo 
Fisher Scientific, USA) according to manufacturer’s instructions.
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Immunohistochemistry. GADD34 and cleaved caspase-3 immunohistochemistry was performed on all tumor 
samples. All slides were haematoxylin counterstained and digitalized (LEICA SCN400, LEICA Microsystems, 
UK). Slides were analyzed and quantified via user-defined algorithms using Definiens Tissue Studio and 
Developer (Definiens AG, Germany). Percentage expression of each marker was measured from mean of per-
centage positive tissue area and percentage positive nuclei. Details of staining, analysis and quantification are 
provided in the supplemental methods.
Statistical analysis. Data were aggregated from pixel data in each tumor, and their median value used as 
a measure of central tendency in subsequent analysis (rather than mean values, in order to limit the influence 
of extreme or outlier values resulting from convergence at local minima). Longitudinal data were normalised to 
the baseline measurement and expressed as a percentage change. Two-way analysis of variance between groups 
(ANOVA) (GraphPad Prism X.6.0.1, USA) was used for statistical analysis. Both the difference between control 
and treated groups at the same time points (between group analysis), and the difference between post-treatment 
and baseline data (within group analysis) were tested for statistical significance. P < 0.05 was considered signifi-
cant. Correlations were assessed using Spearman’s rho.
Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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